1. Home
  2. STEW vs NBTX Comparison

STEW vs NBTX Comparison

Compare STEW & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SRH Total Return Fund Inc.

STEW

SRH Total Return Fund Inc.

N/A

Current Price

$18.67

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

N/A

Current Price

$44.43

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STEW
NBTX
Founded
N/A
2003
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
2.0B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
STEW
NBTX
Price
$18.67
$44.43
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
79.0K
142.4K
Earning Date
01-01-0001
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$58.17
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.55
$8.03
52 Week High
$19.05
$57.14

Technical Indicators

Market Signals
Indicator
STEW
NBTX
Relative Strength Index (RSI) 56.56 53.19
Support Level $18.31 $34.97
Resistance Level $19.05 $41.99
Average True Range (ATR) 0.19 2.17
MACD -0.03 0.15
Stochastic Oscillator 49.40 58.57

Price Performance

Historical Comparison
STEW
NBTX

About STEW SRH Total Return Fund Inc.

SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: